💧 CBD Regulatory Status Comparison Simulator

CBD Source Comparison — Pharma vs Supplement

One molecule, two completely different products under the law.

• 1: FDA-approved CBD drugs (Epidiolex, since 2018)
• $$ Billions: Hemp CBD market size (est.) (largely unregulated)
• <0.3%: Legal THC ceiling (hemp) (dry-weight basis)
• None: FDA supplement rule finalized (still pending)

Pharmaceutical-grade CBD

Epidiolex went through rigorous trials before approval.

One product, full FDA drug review.

Hemp-derived CBD supplements

Legal under Farm Bill, but not FDA-approved as an ingredient.

Why the split confuses consumers

Same three letters, opposite evidence and quality standards.

Pharmaceutical Pathway — Epidiolex

Full FDA drug approval: trials, safety data, manufacturing standards.

• 3: Trial phases completed (plus preclinical work)
• 2018: FDA approval year (first plant-derived cannabinoid drug)
• Seizure disorders: Approved indication (rare epilepsy syndromes)
• cGMP: Manufacturing standard (current good manufacturing practice)

Preclinical & trial design

Years of animal and human trials precede any approval.

NDA review & approval

FDA reviews safety, efficacy, and manufacturing before sign-off.

Every batch is tested to a fixed standard.

Prescription-only dispensing

A doctor, not a shelf label, controls who gets it.

Supplement Pathway — Hemp CBD

Marketed without FDA premarket approval, in a tolerated gray zone.

• No: FDA premarket approval required (for hemp CBD supplements)
• <0.3%: THC limit for legal hemp (2018 Farm Bill threshold)
• Low: FDA enforcement priority (mostly warning letters)
• Voluntary: Independent lab testing (not federally mandated)

Farm Bill exemption

Legalized hemp, but not hemp-derived supplement ingredients.

No premarket FDA review

Products reach shelves without agency evaluation first.

"Not evaluated by the FDA" is the honest label.

Quality varies widely

Potency and purity depend entirely on the brand.

Jurisdictional Variation — Federal vs State

States and countries add their own layer atop federal rules.

• Many: States with added CBD rules (licensing, labeling, bans)
• Several: Countries w/ stricter limits (lower THC or Rx-only)
• THC <0.3%: Federal baseline (Farm Bill standard)
• Low: Consistency across jurisdictions (rules vary widely)

Federal floor, not ceiling

Federal law sets a minimum — states can go further.

Stricter state examples

Some states require licensing, testing, or outright bans.

Legal in one state, restricted in the next.

International divergence

Other countries classify CBD as medicine-only.

Jurisdiction snapshot (illustrative)

Consumer Outcome — One Label, Two Realities

Buyers face a confusing landscape hiding under one shared name.

• Rigorous trials: Evidence standard: pharma track (FDA-reviewed)
• Self-reported: Evidence standard: supplement track (not FDA-reviewed)
• Low: Consumer certainty (without reading labels closely)
• Pending rules: Path forward (FDA framework still incomplete)

Two products, one name

"CBD" can mean a tested drug or an untested supplement.

Quality gap in practice

Label accuracy and purity swing widely in the supplement market.

Ask which track a product actually followed.

What could resolve it

A finalized FDA supplement framework would narrow the gap.